Chronic bronchitis
Tachypnea (28/min): Increased respiratory rate is an attempt to compensate for poor ventilation (decreased O2 , increased CO2). It is also compensation for air trapping with the patient breathing at a very high lung volume.
Fever: Reflects an acute infection superimposed on chronic bronchitis. Early pneumonia? Cytokines affect the thermoregulatory mechanism.
Palpable Liver: Could be either due to CHF or hyper inflated lungs pushing the diaphragm down. Liver span will help you distinguish between the two.
Enlarged nodular prostate. Suggests prostatic hypertrophy with a consideration for malignancy.
Arterial blood gases reveal a chronic respiratory acidosis with complete compensation. There is hypoxia and hypercapnia. The hypoxia is due to poor V/Q matching due to severe COPD.
Hypoxia could be due to
A sputum culture would probably not be ordered routinely in COPD. The sputum culture would probably show mixed flora. A gram stain of the sputum might be a more helpful and economical first step. A sputum culture would be indicated if the first antibiotic failed to clear the infection. Probable organisms causing the respirator infection include Streptococcus pneumoniae, Hemophilus influenza, Branhamella catarrhalis.
The chest x-ray is ordered to rule out pneumonia. There is no evidence for pneumonia. The x-ray shows hyperinflation, low set diaphragm and possibly blebs. The transverse diameter of heart is increased.
Sspirometry.
The most important evidence is that FEV1/FVC is decreased (normal >75%) and is severe (<40%)
The Spirometry results are consistent with an obstructive pattern of pulmonary disease. The forced expiratory volume in 1 second FEV1 measures the average flow rate during the first second of the forced vital capacity (FVC) maneuver, FEV1 declines in direct proportion with clinical worsening of airway obstruction. It increases with successful treatment of airway obstruction. The percent of predicted FEV1 for a normal patient should not slip below 80%. He has severe obstructive defect.
The electrocardiogram show a rate of 80 BPM, normal sinus rhythm and right axis of (+137o); there is right ventricular hypertrophy with strain. The R is greater than S in lead V1 and the T wave is inverted in leads V1-V2. Strain suggests ischemia during diastole in a hypertrophied wall. S waves are deep in the left precordial leads. There is borderline right atrial hypertrophy by voltage, especially noted in leads II and AVF.
Right ventricular hypertrophy is consistent with this patient's clinical problem. He has chronic obstructive pulmonary disease with secondary hypertension and consequent cor pulmonale. Make sure the students understand the pathogenesis of the atrial/ventricular hypertrophy. Also, they should understand the pathogenesis of secondary versus primary pulmonary hypertension.
Chronic Bronchitis: mucous within bronchial lumina; chronic inflammation of the bronchial wall, marked increase in the size of the mucous glands (increase in Reid Index), patches of squamous metaplasia. Acute bronchitis: mucosa/submucosal edema, inflammatory cells (also in sputum).
Emphysema: destruction of alveoli creating large air spaces scattered throughout both lungs. Scattered small pulmonary arteries showing smooth muscle hypertrophy. Hyper inflated lungs.
Right ventricular/right atrial hypertrophy. Chronic passive congestion of the liver.
Antibiotics to treat respiratory infection
Common organisms | Antibiotic | ||
Hemophilus Influenza Streptococcus Pneumoniae Brahmella catarrhalis
|
First line | Second line | Penicillin allergy |
Amoxacillin Doxycycline Trimethaprim/Sulfamethaxazole |
Azithromycin Ciproflaxin Augmentin |
||
Virus |
Treatment of chronic bronchitis
Pathophysiology | Therapeutic option |
Irritation of bronchi by Cigarettes | Stop Smoking |
Narrowing of bronchi::
|
? Steroids Bronchodilators |
Secretions:
|
?Mucolytic agents/Expectorants |
Bronchodilators
Site of action | Bronchodilators |
Beta2 agonists | Albuterol inhalers |
Ipratropium bromide | |
Theophylline |
Congestive Heart failure/Corpulmonale
Pathophysiology | Therapeutic options |
Pulmonary hypertension
|
Continuous Oxygen |
LV dysfunction if any | Digoxin and diuretics |
Pulmonary hypertension
Pathophysiology | Therapeutic option |
Alveolar hypoxia/Vasoconstriction | Oxygen |
Loss of vascular bed | Lung transplant |
Hypoxia
You need to have an understanding of the following statements. Administer oxygen like any medication with consideration for dose and method of delivery.
Physiological basis | Therapeutic option |
Optimal arterial oxygen level.. (Oxygen dissociation curve) | Target PaO2 of 55-60 |
Concern for hypoxic drive (Respiratory centers) | Titrate Oxygen to maintain pH over 7.25 |
Hypoxia due to V/Q mismatch is easily correctable | Low FIO2: 1-4 Liters by nasal cannula |
High flow and low flow (Oxygen delivery systems) | Acute phase: High flow (Venturi mask)
Stable phase: Low flow (Nasal cannula) |
Work of breathing
Pathological basis | Therapeutic options |
Increased airway resistance | Bronchodilators |
Airway collapse | Pursed lip breathing |
Inefficient Diaphragmatic position | Lean forward with diaphragmatic breathing |
Anxiety | No sedatives for fear of respiratory depression |
Role for steroids
Pathophysiology/Anti-inflammatory | Clinical setting |
Acute bronchitis | Acute Exacerbation |
Chronic bronchitis | ? Chronic use |
Emphysema
Pathpphysiology | Therapeutics |
Loss of alveolar septa/and elastic recoil/hyperinflation/Blebs and bullae | Lung reduction Surgery |
Lung Transplant | |
Loss of capillary bed/Pulmonary hypertension | Heart/Lung Transplant |
Smoking cessation